Germany’s BioNTech SE reported second-quarter revenue of €260.8 million, comfortably ahead of analyst estimates, but the Covid-19 vaccine maker remained in the red as pandemic demand continued to fade. The company posted a net loss of €386.6 million, or €1.60 per share, wider than the consensus forecast. Management maintained full-year guidance for €1.7 billion to €2.2 billion in revenue and €2.6 billion to €2.8 billion in operating expenses, highlighting a cash pile of €16 billion to fund an expanding oncology pipeline that now includes the planned acquisition of rival mRNA developer CureVac. Swiss staffing giant Adecco Group AG also topped expectations, booking second-quarter net income of €58 million on revenue of €5.78 billion. While adjusted EBITA of €141 million slightly exceeded forecasts, the gross margin slipped 50 basis points year on year to 18.9 percent as slower economic activity weighed on pricing. Logistics heavyweight Deutsche Post DHL Group turned in mixed numbers. Second-quarter revenue fell short of estimates at €19.83 billion, yet operating profit beat at €1.43 billion. The company reaffirmed its full-year target of at least €6 billion in EBIT and about €3 billion in free cash flow, signalling confidence in cost controls even as volumes soften.